# Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients

> **NCT02473497** · — · NO_LONGER_AVAILABLE · sponsor: **Pfizer**

## Conditions studied

- Neoplasm

## Interventions

- **DRUG:** Crizotinib

## Key facts

- **NCT ID:** NCT02473497
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2024-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02473497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02473497, "Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02473497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*